Screening For Left Ventricular Dysfunction May Have Less Value Than Thought

The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.

More: continued here

Filed under: Hypertension on June 22nd, 2009